Economic aspects of commercial manufacture of biopharmaceuticals.
about
Industrialization of mAb production technology: the bioprocessing industry at a crossroadsDesign of a binding scaffold based on variable lymphocyte receptors of jawless vertebrates by module engineeringAlternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities.Anticalins: the lipocalin family as a novel protein scaffold for the development of next-generation immunotherapies.Efficient production of human bivalent and trivalent anti-MUC1 Fab-scFv antibodies in Pichia pastorisModification of the loops in the ligand-binding site turns avidin into a steroid-binding protein.Directed evolution of three-finger toxin to produce serine protease inhibitors.Engineering eukaryotic protein factoriesFactors of importance for a successful delivery system for proteins.The role of recombinant proteins in the development of serum-free media.Improved antibody production in Chinese hamster ovary cells by ATF4 overexpressionChallenges in monoclonal antibody-based therapies.Downstream Processing Technologies/Capturing and Final Purification : Opportunities for Innovation, Change, and Improvement. A Review of Downstream Processing Developments in Protein Purification.Bioreactor productivity and media cost comparison for different intensified cell culture processes.Scaled-up manufacturing of recombinant antibodies produced by plant cells in a 200-L orbitally-shaken disposable bioreactor.Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity.Lyophilized silk fibroin hydrogels for the sustained local delivery of therapeutic monoclonal antibodies.Enhancement of antibody production by the addition of Coenzyme-Q(10).Different expression systems for production of recombinant proteins in Saccharomyces cerevisiaeTranscriptomics-based identification of novel factors enhancing heterologous protein secretion in yeasts.Fluid flow through a high cell density fluidized-bed during centrifugal bioreactor culture.Pichia pastoris secretes recombinant proteins less efficiently than Chinese hamster ovary cells but allows higher space-time yields for less complex proteinsTechno-economic analysis of a transient plant-based platform for monoclonal antibody production.Engineering of chaperone systems and of the unfolded protein response.Versatile modeling and optimization of fed batch processes for the production of secreted heterologous proteins with Pichia pastoris.Glycoengineering of antibody (Herceptin) through yeast expression and in vitro enzymatic glycosylation.Process change evaluation framework for allogeneic cell therapies: impact on drug development and commercialization.Expression and Control of Codon-Optimized Granulocyte Colony-Stimulating Factor in Pichia pastoris.Albumin 3'untranslated region facilitates increased recombinant protein production from Chinese hamster ovary cells.Process analytical technology (PAT) for biopharmaceuticals.Economics of recombinant antibody production processes at various scales: Industry-standard compared to continuous precipitation.Non-Antibody Scaffolds as Alternative Therapeutic Agents
P2860
Q24655304-4EA46F04-18D3-46DF-8D73-FBCD3234ED9BQ27677231-FEE5ED3E-DD7C-4908-8868-57E429555161Q30157688-3BD15103-62A6-48B2-8BA0-647FDF688048Q30157932-0B3343AE-ADF7-43B9-8A6B-24751A42B181Q33492560-ABF848D4-DF63-4AE1-A6D8-81349898DB96Q33928111-988B027E-1159-4786-AAB4-2A4DADBD98E9Q35059556-E2570CF2-7E50-48BE-B2E1-EE5068CBE399Q36296459-09B94E6B-6B96-462D-AA13-9F647FF2068BQ36316926-60B66EDD-747E-4C9D-8AEA-0172BCAF1A58Q36331919-15179B5F-FA9B-4C59-B52A-46DC13F08390Q37369571-DAE3BC2D-2CF9-4793-BB86-B80B095DBA6DQ37398725-1B98ECB6-D54F-4615-B37C-075C2A3C2E37Q38631194-E0BCE51C-6A76-42E6-A097-4EFF508F9B38Q38726126-F7D68824-5B87-4599-BBA7-FBE7A6D08DF0Q38966696-69284F37-6260-468A-AF26-FA1E33B0928DQ39484103-FDD7876E-F7BE-454B-B2AA-2741CEE101BAQ39610634-DAFAD38E-44E4-4ED7-8FF9-9B89E1AFB8A2Q39613088-834ED3AD-C68A-426E-96DC-E3D7E590A756Q39674543-91D07D5D-7809-4195-A30C-B156203F0794Q40006859-2DB69B90-4E1D-465D-83CD-0863A903003DQ41195518-98411FB3-E33A-4189-B2ED-7DD06D59C506Q41986845-D3FBD3ED-417D-416E-98C5-1B91A610727AQ42373048-5744C862-817F-4421-B39D-8ACB65EC0983Q42837135-116F2799-FFBC-43C7-932E-6018110D965CQ43109122-4881A430-2235-45E7-A36C-5ECD533EB41FQ50133462-B3CAEB57-9938-4091-9674-215FF31B47DBQ51442619-847F88AC-B859-4742-BE85-E0070F55E84CQ51705908-82AE20E3-BAC8-4C09-ADD5-9988E151A747Q51758863-F060A61B-A224-4AC4-83A2-13EE0DA7777FQ51769026-71A9DA07-EE5F-4177-BA36-485D9CD9DFECQ53580907-752B0997-6EC9-42F3-9AB6-ED2577CA2DD7Q57260221-07B793CF-146F-4E72-9986-2DE889282DF6
P2860
Economic aspects of commercial manufacture of biopharmaceuticals.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Economic aspects of commercial manufacture of biopharmaceuticals.
@ast
Economic aspects of commercial manufacture of biopharmaceuticals.
@en
type
label
Economic aspects of commercial manufacture of biopharmaceuticals.
@ast
Economic aspects of commercial manufacture of biopharmaceuticals.
@en
prefLabel
Economic aspects of commercial manufacture of biopharmaceuticals.
@ast
Economic aspects of commercial manufacture of biopharmaceuticals.
@en
P1476
Economic aspects of commercial manufacture of biopharmaceuticals.
@en
P2093
Rolf G Werner
P304
P356
10.1016/J.JBIOTEC.2004.04.036
P577
2004-09-01T00:00:00Z